Precigen
Precigen's revenue rose 146.7% to $10 million in fiscal 2025. Its operating margin was −1,141.1%, up from −3,440.2% a year earlier. Free cash flow was −$90 million. The diluted share count rose 16.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Precigen does
Precigen is a biopharmaceutical company that develops gene-based medicines for immuno-oncology, autoimmune disorders and infectious diseases. In August 2025 the US Food and Drug Administration granted full approval to its first product, Papzimeos, for adults with recurrent respiratory papillomatosis, a rare and potentially life-threatening condition. It is caused by long-lasting infection with certain human papillomaviruses, which results in repeated benign tumors in the airways. Papzimeos is an immunotherapy that uses a harmless adenovirus to teach the immune system to attack cells infected with those viruses.
Precigen builds its medicines on its own technology platforms. AdenoVerse is the adenovirus-based one behind Papzimeos and the candidate PRGN-2009. UltraCAR-T modifies a patient's immune cells to fight cancer, and Precigen developed a device called UltraPorator to make those treatments faster and more cheaply. It continues Phase 2 trials of PRGN-2009 in cervical cancer and in oropharyngeal cancer, in agreement with the National Cancer Institute. It has finished enrolling a Phase 1b trial of PRGN-3006, and in August 2024 it paused enrollment in two other UltraCAR-T trials to focus its pipeline.
Precigen now has a product on the market, but it has lost money since it started, with the exception of 2022. It says its revenue depends largely on Papzimeos and that it has debt and will need substantial capital.
Its biggest risks, as it describes them
- Depending heavily on the commercial success of Papzimeos in the United States and elsewhere.
- A history of net losses, and uncertainty about reaching or keeping profitability.
- Large future capital needs, and debt payments that could limit its operations.
- Markets for its product and candidates that may be smaller than it estimates.
- Early drug candidates that may fail in trials or lack regulatory approval.
Income statement
Precigen lost money in fiscal 2025: a net loss of $251 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 109 | 56 | 63 | 98 | 100 |
| Debt incl. finance leases | 180 | 86 | — | 0 | 93 |
| Net debt (negative means net cash) | 71 | 31 | — | −98 | −7 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.7x | 0.7x | — | 0.0x | 4.5x |
| Interest coverage | −14.5x | −8.4x | −213.2x | −22,504.8x | −28.6x |
| Current ratio | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
| Quick ratio | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
Cash flow
Projections
Project Precigen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Precigen reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 2 of 8 |
| Rule of 40 | −1,176.7% | −1,992.5% | −780.9% |
| Altman Z'' | −41.03 | −49.00 | −50.41 |
| Accruals ratio | −15.8% | −39.2% | −108.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | 2 of 8 |
Compare
Put Precigen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | |
| Zenas BioPharma | FY25 | 100.0% | −3,830.6% | −1,723.5% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 191 | 231 | 151 | 91 | 32 | 14 | 27 | 6 | 4 | 10 |
| Revenue growth | 10.0% | 21.0% | −34.5% | −40.0% | −64.7% | −55.4% | 88.6% | −76.9% | −37.0% | 146.7% |
| Gross profit | 153 | 198 | — | — | — | — | — | — | — | — |
| Research and development | 112 | 143 | 405 | — | — | — | — | 49 | 53 | 41 |
| Operating income | −125 | −138 | −506 | — | — | — | — | −100 | −135 | −110 |
| Net income | −187 | −117 | −509 | −322 | −170 | −92 | 28 | −96 | −126 | −251 |
| Diluted EPS (US$) | −1.58 | −0.98 | −3.93 | −2.09 | −1.02 | −0.47 | 0.14 | −0.39 | −0.47 | −1.37 |
| Diluted shares (millions) | 118 | 120 | 130 | 154 | 167 | 198 | 200 | 244 | 268 | 313 |
| Cash flow | ||||||||||
| Cash from operations | −49 | −104 | −124 | −136 | −77 | −56 | −65 | −67 | −68 | −88 |
| Capital expenditure | 32 | 47 | 42 | 38 | 8 | 7 | 5 | 2 | 9 | 2 |
| Free cash flow | −81 | −150 | −166 | −174 | −85 | −63 | −70 | −68 | −77 | −90 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 42 | 42 | 36 | 19 | 18 | 14 | 10 | 10 | 10 | 11 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 237 | 74 | 222 | 75 | 100 | 109 | 56 | 63 | 98 | 100 |
| Debt incl. finance leases | 8 | 8 | 212 | 218 | 172 | 180 | 86 | — | 0 | 93 |
| Total assets | 949 | 847 | 716 | 456 | 315 | 360 | 216 | 151 | 145 | 156 |
| Total liabilities | 380 | 300 | 338 | 384 | 247 | 252 | 90 | 32 | 78 | 135 |
| Shareholders' equity | 560 | 534 | 363 | 72 | 67 | 107 | 126 | 118 | 38 | 21 |
| Margins and ratios | ||||||||||
| Gross margin | 80.2% | 85.6% | — | — | — | — | — | — | — | — |
| Operating margin | −65.6% | −59.7% | −334.4% | — | — | — | — | −1,602.5% | −3,440.2% | −1,141.1% |
| Net margin | −97.7% | −50.7% | −336.9% | −355.3% | −533.0% | −646.0% | 105.2% | −1,540.6% | −3,216.2% | −2,588.2% |
| Free cash flow margin | −42.2% | −65.1% | −109.7% | −191.6% | −264.3% | −441.7% | −260.0% | −1,099.9% | −1,955.6% | −927.6% |
| Rule of 40 (growth + FCF margin) | −32.2% | −44.1% | −144.2% | −231.6% | −329.0% | −497.1% | −171.4% | −1,176.7% | −1,992.5% | −780.9% |
| Return on capital | −24.3% | −26.6% | −94.2% | −45.4% | −43.5% | −51.6% | −33.6% | — | — | — |
| Return on equity | −29.8% | −21.4% | −113.6% | −148.3% | −245.6% | −105.6% | 24.2% | −78.4% | −160.8% | −843.6% |
| Return on assets | −19.3% | −13.0% | −65.2% | −55.0% | −44.3% | −27.3% | 9.8% | −52.3% | −85.2% | −166.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |